Aktienanalyse zu IQVIA Holdings Inc (IQV)IQVIQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.